Hodgkin lymphoma Clinical Trials
Recruiting hodgkin lymphoma studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.
Clinical trials study new ways to prevent, detect, or treat hodgkin lymphoma. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting hodgkin lymphoma studies with sites across the US; use the location tools to find ones near you.
What to expect
- Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
- Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
- No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.
Recruiting hodgkin lymphoma trials
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
CD45BE-HSPC + CART-45 Cells
PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma
Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma
A Phase I Study of JLM019 Injection
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
Genetic Markers of Susceptibility to Chemotherapy-induced Ovarian Damage in Cancer Patients Undergoing Ovarian Biopsy for Cryopreservation.
A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
PTCy and ATG for MSD and MUD Transplants
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
The Pathogenesis and Prognostic Factors of Lymphoma
Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Lifestyle Intervention of Food and Exercise for Lymphoma Survivors
Improving Exercise Capacity With a Tailored Physical Activity Intervention
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
Early Ageing During Therapy in AYA Cancer Patients
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
Two Step Haplo With Radiation Conditioning
Hodgkin lymphoma clinical trials — common questions
Are hodgkin lymphoma clinical trials free to join?
Yes. Participating in a hodgkin lymphoma clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.
Who can join a hodgkin lymphoma clinical trial?
Each hodgkin lymphoma study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.
How do I find a hodgkin lymphoma trial near me?
Use the location controls above. We'll show recruiting hodgkin lymphoma trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.
How many hodgkin lymphoma trials are recruiting right now?
We're currently tracking roughly 39 recruiting hodgkin lymphoma trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.
Looking for a specific location? Browse trials by city and state.